TAIAN CITY, Shandong, China, Aug. 13 /Xinhua-PRNewswire-FirstCall/ -- China Biologic Products, Inc. (BULLETIN BOARD: CBPO) ('CBP,' or the 'Company'), one of the leading plasma-based pharmaceutical companies in the People's Republic of China ('PRC'), today announced that, effective August 7, 2008, its Board of Directors has established a Governance and Nominating Committee and a Compensation Committee, and has appointed each of the Company's current independent directors, Dr. Tong Jun Lin, Dr. Jie Gan and Mr. Sean Shao, as members of each committee. Dr. Lin was appointed to serve as Chair of the Governance and Nominating Committee and Dr. Gan was appointed to serve as Chair of the Compensation Committee.
'We are delighted to have all our board committees in place, with each of our independent directors as chairpersons of their respective committees,' said Mr. Chao Ming Zhao, the Company's CEO. 'The establishment of these new board committees is another step in furtherance of our new corporate governance policy, as we continue to expand our business and pursue our commercial objectives.'
Mr. Sean Shao, independent director and Chairman of CBP's Audit Committee, has been appointed as a member of the Governance and Nominating Committee and the Compensation Committee. Mr. Shao brings to CBP over thirteen years of experience in financial and operational management in publicly held and private-owned companies. For the past four years Mr. Shao has served as chief financial officer of Trina Solar Limited, ChinaEdu Corporation, a Chinese educational service provider, and Watchdata Technologies Ltd., a Chinese security software company. Prior to this, Mr. Shao served six years as a senior manager at Deloitte Touche Tohmatsu Beijing and three years with Deloitte & Touche Toronto. Mr. Shao received his master's degree in health care administration from the University of California at Los Angeles in 1988 and his bachelor's degree in art from East China Normal University in 1982. Mr. Shao holds a CPA license of American Institute of Certified Public Accountants.
Dr. Jie Gan, independent director and member of CBP's Audit Committee, has been appointed to serve as the Chair of CBP's Compensation Committee and as a member of the Governance and Nominating Committee. Dr. Gan brings a wealth of financial consulting experience to CBP. She serves as an associate professor with tenure in the Department of Finance at the Hong Kong University of Science and Technology. Her areas of research expertise include pharmaceutical company valuation in the areas of accounting statements, cash flow forecasts, and cost of capital estimations. Dr. Gan received her PhD in Financial Economics from the Massachusetts Institute of Technology and her Bachelor's degree from Nanjing University in China.
Dr. Tong Jun Lin, independent director and member of CBP's Audit Committee, has been appointed to serve as the Chair of CBP's Governance and Nominating Committee and as a member of the Compensation Committee. Dr. Lin has over 20 years of medical research experience. He is an associate professor with tenure in the Departments of Microbiology and Immunology and Pediatrics at the Dalhousie University. Dr. Lin has been involved in the studies of immunological mechanisms in the host defense against microbial pathogens and allergens. Dr. Lin received his MD (1984) from The First Military Medical University in Guangzhou, China and PhD (1990) degree from the Institute of Materia Medica Chinese Academy of Medical Sciences in Beijing, China. He received his post-doctoral training at the University of Alberta, Duke University and Dalhousie University.
About China Biologic Products, Inc.
Through its indirect majority-owned subsidiary Shandong Taibang Biological Products Co. Ltd., China Biologic Products, Inc. (the 'Company'), is principally engaged in the research, development, production and manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. The Company's human albumin products are mainly used to increase blood volume and its immunoglobulin products are used for the treatment and prevention of diseases.
Safe Harbor Statement
This release may contain certain 'forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiary companies. All statements, other than statements of historical fact included herein are 'forward-looking statements," including statements regarding: the significance of the Company's establishment of the new board committees; the ability of the Company to achieve its commercial objectives; the business strategy, plans and objectives of the Company and its subsidiaries; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as 'believes,' 'expects' or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website ( http://www.sec.gov/ ). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
For more information, please contact:
Company Contact:
Mr. Y. Tristan Kuo, CFO
China Biologic Products, Inc.
Tel: +86-538-6202-206
Email:
